Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry.
Tsutomu MurakamiYusuke WatanabeNorihito NakamuraMakoto NatsumedaYohei OhnoGaku NakazawaYuji IkariAkihisa KataokaYosuke NishihataKentaro HayashidaMasanori YamamotoJun TanakaKentaro JujoMasaki IzumoKazuki MizutaniKen KozumaPublished in: Heart and vessels (2024)
Short-term treatment with tolvaptan improved HF in patients hospitalized for severe AS, regardless of the presence of AF or SR. After achieving sufficient diuresis, a slight decrease in blood pressure was observed in the AF group, suggesting an appropriate timeframe for safe and effective use of tolvaptan.
Keyphrases
- ejection fraction
- atrial fibrillation
- heart failure
- aortic stenosis
- acute heart failure
- blood pressure
- end stage renal disease
- aortic valve replacement
- left ventricular
- transcatheter aortic valve replacement
- liver failure
- transcatheter aortic valve implantation
- aortic valve
- newly diagnosed
- chronic kidney disease
- left atrial
- polycystic kidney disease
- oral anticoagulants
- early onset
- drug induced
- peritoneal dialysis
- direct oral anticoagulants
- prognostic factors
- intensive care unit
- mitral valve
- percutaneous coronary intervention
- heart rate
- metabolic syndrome
- cardiac resynchronization therapy
- acute coronary syndrome
- type diabetes
- coronary artery disease
- respiratory failure
- hypertensive patients
- acute respiratory distress syndrome
- patient reported outcomes
- patient reported
- skeletal muscle
- blood glucose
- replacement therapy
- mechanical ventilation